Drug · CHEMBL460
MOLINDONE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. MOLINDONE. Drugs and targets, record CHEMBL460. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL460
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| DRD2 | D(2) dopamine receptor | Dopamine D2 receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/1813 |
| HTR2A | 5-hydroxytryptamine receptor 2A | Serotonin 2a (5-HT2a) receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/3356 |
Source ChEMBL
Diseases3
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| attention deficit-hyperactivity disorder | Phase 3 | ClinicalTrials.gov and TTD | 9 | 8 | https://conductscience.org/library/drugs?q=MONDO_0007743 |
| psychotic disorder | Approval | ATC | 1 | 0 | https://conductscience.org/library/drugs?q=MONDO_0005485 |
| schizophrenia | Approval | TTD | 1 | 0 | https://conductscience.org/library/drugs?q=MONDO_0005090 |
Source Open Targets
Trials9
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02691182 | Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4) | Phase 3 | 491 | 2024-05-16 | SPN-810 | Its name | ClinicalTrials.gov |
| NCT02618408 | Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1) | Phase 3 | 333 | 2022-11-01 | SPN-810 | Its name | ClinicalTrials.gov |
| NCT02618434 | Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2) | Phase 3 | 297 | 2024-03-18 | SPN-810 | Its name | ClinicalTrials.gov |
| NCT00053703 | Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS) | Phase 4 | 116 | 2014-03-26 | molindone | Its name | ClinicalTrials.gov |
| NCT00626236 | Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems | Phase 2 | 78 | 2025-09-16 | molindone | Its name | ClinicalTrials.gov |
| NCT03597503 | Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment | Phase 3 | 41 | 2024-02-20 | SPN-810 | Its name | ClinicalTrials.gov |
| NCT03638466 | Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD | Phase 2 | 7 | 2025-05-02 | SPN-810 | Its name | ClinicalTrials.gov |
| NCT01364662 | A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 2 | 121 | spn-810 | Its name | ClinicalTrials.gov | |
| NCT01416064 | Open-Label, Extension Study to 810P202 | Phase 2 | 78 | molindone | Its name | ClinicalTrials.gov |
Comparisons in its trials4
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Flexible Dose of SPN-810 vs Placebo: deaths from any cause | 0 of 21 | 0 of 20 | 41 | NCT03597503 | Trial comparisons |
| Flexible Dose of SPN-810 vs Placebo: serious adverse events | 0 of 21 | 0 of 20 | 41 | NCT03597503 | Trial comparisons |
| High Dose SPN-810 vs Placebo: deaths from any cause | 0 of 3 | 0 of 4 | 7 | NCT03638466 | Trial comparisons |
| High Dose SPN-810 vs Placebo: serious adverse events | 0 of 3 | 0 of 4 | 7 | NCT03638466 | Trial comparisons |
Papers from its trials9
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| Point Subtraction Aggression Task | 1 | 1 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL460
GET https://conductscience.org/api/drugs/v1/CHEMBL460/targets